EPDS vs. PHQ-9 vs. GAD-7: Choosing a PMAD Screening Tool for OB and Midwifery Practices

Approximately 1 in 5 postpartum patients in a typical OB practice will develop a clinically significant perinatal mood and anxiety disorder (PMAD). Most will not self-report. The tool you use to screen them matters less than having a consistent protocol, but tool selection does affect what you catch, when you catch it, and how confident you can be in the result.

This guide compares the three most commonly used instruments in perinatal primary care: the Edinburgh Postnatal Depression Scale (EPDS), the Patient Health Questionnaire-9 (PHQ-9), and the Generalized Anxiety Disorder 7-item scale (GAD-7). It covers cutoff scores, validated sensitivity and specificity data, timing recommendations, and the cases where combining tools is worth the extra two minutes.

---

Quick-Reference Comparison

---

The EPDS: The Perinatal Standard

The Edinburgh Postnatal Depression Scale is the only screening instrument validated specifically for perinatal populations. Cox, Holden, and Sagovsky developed it in 1987 with perinatal-specific validation studies, and it has since been validated in more than 20 languages across diverse clinical settings. The EPDS is the instrument ACOG references in Practice Bulletin 343 and the one USPSTF uses when discussing perinatal depression screening.

The design addresses a real limitation of general depression tools: several common postpartum symptoms (poor sleep, fatigue, reduced libido, appetite changes) overlap with normal postpartum physiology. The EPDS avoids somatic items and focuses on mood, anhedonia, anxiety, and self-harm ideation. A new mother who is exhausted because she has a four-week-old and is not sleeping will not be falsely flagged by the EPDS the way she might be by the PHQ-9.

Score interpretation:

• 0–9: Low concern. Routine monitoring; repeat at next scheduled screen.
• 10–12: Elevated. Clinical assessment warranted. Explore context, risk factors, and functional impairment. This range is not diagnostic, but it should not be filed and forgotten.
• 13–30: Probable major depression. Referral to perinatal mental health or immediate treatment planning is indicated.
• Item 10 score > 0: Any acknowledgment of self-harm thoughts, regardless of total score, requires direct follow-up before the patient leaves the office. Do not defer to the next visit.

The EPDS items 3, 4, and 5 screen for anxiety (blaming yourself, feeling scared or panicky, things getting on top of you). This is not a validated anxiety subscale, but scores of ≥6 on these three items correlate with clinically significant anxiety and often indicate the need for further anxiety-specific assessment.

When to choose EPDS: For all routine perinatal screening. It is the most appropriate first-line tool for OB and midwifery practices.

---

The PHQ-9: Useful in Its Lane

The PHQ-9 is the most widely used depression screener in primary care, and it works well in that context. In perinatal care, it has two meaningful limitations.

First, four of its nine items (sleep, fatigue, appetite, psychomotor changes) are heavily influenced by normal postpartum physiology. A patient who is exclusively breastfeeding a six-week-old and sleeping in two-hour intervals will almost certainly score elevated on these items without having a depressive disorder. The PHQ-9 was validated in primary care adult populations, not in postpartum cohorts. Studies comparing it to the EPDS in postpartum patients consistently show higher false positive rates with the PHQ-9.

Second, it does not screen for anxiety. PMADs include generalized anxiety, panic disorder, and OCD at clinically significant rates, and a tool that only screens for depression will miss those presentations.

Where the PHQ-9 earns its place: tracking depression severity over time in patients who are already diagnosed and receiving treatment. The 5-point minimally important difference on the PHQ-9 is well established, making it useful for monitoring treatment response at follow-up visits. Using it as the primary screen in a perinatal population, though, means accepting a higher rate of false positives and missing anxiety-predominant presentations.

When to use PHQ-9 in perinatal care: As a severity tracking tool in patients already identified through EPDS screening. Not as a first-line screen.

---

The GAD-7: Filling the Anxiety Gap

The EPDS partial-anxiety screen captures something, but it was not designed as an anxiety instrument. If your practice sees patients with predominant anxiety presentations (postpartum panic, intrusive thoughts, hypervigilance, excessive worry about infant health), the GAD-7 adds specificity that the EPDS does not provide.

The GAD-7 was validated for generalized anxiety disorder in primary care populations. Its sensitivity for GAD is approximately 89%, and its specificity is approximately 82% at a threshold of 10. It also performs reasonably well for panic disorder and social anxiety disorder, though it was not validated for perinatal-specific anxiety subtypes like postpartum OCD.

Score interpretation:

• 0–4: Minimal anxiety. Monitor.
• 5–9: Mild anxiety. Discuss with patient; assess functional impact and context.
• 10–14: Moderate anxiety. Clinical evaluation warranted; consider referral.
• 15–21: Severe anxiety. Referral indicated.

When to add GAD-7: When a patient's EPDS score is below the depression threshold (less than 13) but she is describing prominent anxiety symptoms, or when anxiety items on the EPDS (items 3–5) are elevated relative to the depression items. The EPDS and GAD-7 together take approximately five to six minutes to complete and give a more complete picture than either alone.

Postpartum OCD deserves specific mention. The GAD-7 does not screen reliably for OCD, and if you are seeing patients with distressing, repetitive intrusive thoughts (particularly about harming the baby), a direct clinical interview is more appropriate than relying on either instrument. Postpartum OCD is significantly underdiagnosed in OB settings; the symptoms are frequently not volunteered by patients because of shame and fear of consequences.

---

Combining Instruments: The EPDS + GAD-7 Pairing

For practices wanting a more complete anxiety screen without adding significant time burden, the EPDS plus GAD-7 is the most practical combination. Together they cover:

• Depression (EPDS primary function)
• Anxiety symptoms in the perinatal context (EPDS items 3–5 as a flag)
• Generalized anxiety with validated severity thresholds (GAD-7)
• Self-harm ideation (EPDS item 10)

The PHQ-9 adds less in this pairing because it overlaps substantially with the EPDS on depression detection and adds somatic items that create false positives. Practices that currently use PHQ-9 as their primary screen can transition to EPDS without meaningful loss of sensitivity and with meaningful gain in specificity for postpartum populations.

---

Timing: When to Screen

ACOG and USPSTF recommend screening at least once during the perinatal period. Current evidence and clinical consensus support a more frequent protocol:

Patients with a prior PMAD history, current social stressors (housing, relationship conflict, lack of support), history of trauma, or a multiple gestation benefit from more frequent screening. In these cases, screening at every visit is clinically defensible and increasingly standard practice.

---

Score-Positive Responses: The Critical Step

Screening without a defined response protocol is not an effective system. An EPDS of 13 that gets documented and deferred is not a screen that helped anyone.

For every score above threshold, define in advance:

1. Who reviews the score before the patient is discharged?
2. What happens at a score of 10–12 vs. 13+?
3. Who initiates the referral conversation?
4. What is the referral pathway?

On how to build that protocol into your practice workflow, see how to set up a postpartum depression screening workflow in your OB practice.

For guidance on what to look for when establishing a perinatal mental health referral relationship (PMH-C certification, wait times, telehealth, and insurance), see choosing a perinatal mental health referral partner for OB practices.

If your practice is ready to establish a referral pathway to perinatal mental health specialists, Phoenix Health therapists hold PMH-C certification and respond to referrals within one business day. We coordinate directly with your patient from first contact, so the handoff is warm rather than a cold "here is a phone number." For practices interested in setting up a standing referral arrangement, contact our clinical partnerships team.

---

FAQ

EPDS Cutoff Scores for Clinical Thresholds

An EPDS score of 10 or higher warrants clinical assessment for a possible PMAD. A score of 13 or higher meets the threshold for probable major depression and should prompt referral or immediate treatment planning. Any score above zero on item 10 (self-harm thoughts) requires direct follow-up regardless of total score.

PHQ-9 Limitations in Perinatal Screening

The PHQ-9 was not designed for perinatal populations. Several items (sleep, fatigue, appetite) can be elevated by normal postpartum physiology, which tends to inflate scores and increase false positives. The EPDS is preferred for routine perinatal screening. PHQ-9 is most useful for tracking depression severity in patients already under treatment.

When to Add GAD-7 to EPDS Screening

The EPDS detects anxiety symptoms through items 3–5, but it was validated primarily for depression. If a patient scores below the EPDS depression threshold but presents with prominent anxiety symptoms, adding the GAD-7 gives a more precise picture. A GAD-7 score of 10 or higher indicates moderate-to-severe generalized anxiety and warrants clinical evaluation.

How Often to Screen During the Perinatal Period

ACOG recommends screening at least once during the perinatal period, and USPSTF recommends annual screening for depression in all adults. In practice, most guidelines support screening at the first prenatal visit, third trimester, postpartum visit (4–6 weeks), and at well-child visits through 6 months postpartum. Higher-risk patients benefit from screening at every encounter.